A new monoclonal antibody called clesrovimab has been recommended for infants to prevent RSV, stirring debate among health experts and advocates. The FDA approved the treatment just weeks ago.
Merck's new drug ENFLONSIA has received FDA approval for preventing RSV in newborns and infants, promising significant reductions in hospitalizations and severe respiratory illness. This long-acting monoclonal antibody offers hope for parents facing RSV season challenges.
